PV Bulletin

ZUBB Dietary Supplement may be harmful due to hidden ingredient

The Food and Drug Administration advises consumers not to purchase or use ZUBB Dietary Supplement, which may contain a harmful hidden ingredient.

Primary source: form

PV Impact Brief

Urgency: HighConfidence: high

What changed

Consumers are advised not to purchase or use ZUBB Dietary Supplement due to the presence of sildenafil, an ingredient not listed on the label.

Why it matters

This advisory addresses potential health risks from a dietary supplement, emphasizing the importance of transparency in product labeling and safety.

Action needed

Healthcare professionals and consumers are directed to report any adverse events related to the use of ZUBB Dietary Supplement to the FDA's MedWatch Program.

Relevant for
Medical Safety LeadSignal Management Lead
Processes impacted
Signal Management
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Evidence and confidence

Confidence: highSource updated: Sep 4, 2026

Full briefing

Practical implication

Healthcare professionals and consumers are directed to report any adverse events related to the use of ZUBB Dietary Supplement to the FDA's MedWatch Program.

The FDA has issued an advisory against the purchase or use of ZUBB Dietary Supplement due to undisclosed sildenafil, posing serious health risks.

What changed: Consumers are advised not to purchase or use ZUBB Dietary Supplement due to the presence of sildenafil, an ingredient not listed on the label.

Why it matters: This advisory addresses potential health risks from a dietary supplement, emphasizing the importance of transparency in product labeling and safety.

Practical implication: Healthcare professionals and consumers are directed to report any adverse events related to the use of ZUBB Dietary Supplement to the FDA's MedWatch Program.

View original source

  • Source: FDA - What's New Drugs RSS
  • Published at source: 2026-09-04T00:00:00.000Z
  • Discovered by monitor: 2026-09-04T21:35:40.450Z

Published from the regulator source ingestion pipeline after PV impact triage.

#Safety Signals#Usa#Fda.gov#Safety Signal#Source-ingestion#Regulator-monitor

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Update product labeling to include new efficacy data and boxed warnings, incorporate the new treatment into compliance protocols, and increase monitoring for adverse events associated with Etcamah.

LabelingSignal ManagementLabeling Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Labeling Lead, Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicFDA · USA · Updated Sep 4, 2026

FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer

Urgency: High

Update labeling and monitoring protocols to include new prescribing information, dosage guidelines, and risk communications related to the potential cardiac risks associated with camizestrant.

LabelingRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Labeling Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicFDA · USA · Updated Sep 4, 2026

FDA Issues Temporary Policies for Compounding Starter Parenteral Nutrition Drug Products

Urgency: High

Healthcare providers and compounding facilities should implement the new temporary policies under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act to ensure compliance and access to essential nutrition products.

Country ComplianceVendor OversightRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Vendor Oversight Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 3, 2026Translated From French

Field Safety Notices: 24 to 28 August 2026

Urgency: High

Healthcare professionals must act on the issued FSNs as outlined by MHRA, ensuring compliance to address any safety concerns associated with the listed medical devices.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Devices
Read impact briefarrow_forward